GlaxoSmithKline (GSK) Completes Tender Offer for Shares of Genelabs (GNLB)
More News related to GNLB
- Notable Mergers and Acquisitions of the Day 1/7: SAY, DSCP, GSK/GNLB
- GlaxoSmithKline (GSK) Completes Tender Offer for Shares of Genelabs (GNLB)
- Notable Mergers and Acquisitions of the Day 12/30: HSSO/EMAG, WSTF, GSK/GNLB
- GlaxoSmithKline (GSK) Reduces Minimum Tender Condition and Extends Tender Offer To Acquire Genelabs Technologies (GNLB)
- GlaxoSmithKline (GSK) Reduces Minimum Tender Condition and Extends Tender Offer To Acquire Genelabs Technologies
More News related to GSK
- Trading Review for Vivus Inc. Issued by Beacon Equity
- Trading Overview for Sinobiopharma Inc. Issued by StockPreacher.com
- bioMerieux and GSK Sign Theranostics Agreement to Develop Predictive Test for Selecting Breast Cancer Treatment
- Unusual 11 Mid-Day Movers 11/16: SPEX, NLST, DRAM, XJT Higher; PARD, CRXX, CAEI, CHIO Lower
- Notable Analyst Rating Changes 11/16: COH, JWN, GNK, ESEA, SVA, YGE Upgraded; PARD, GPS, JCP, DLTR Downgraded
GlaxoSmithKline plc (NYSE: GSK) announced the successful completion of the tender offer by its wholly-owned subsidiary Gemstone Acquisition Corporation for shares of common stock of Genelabs Technologies, Inc. (Nasdaq: GNLB). The tender offer expired at 12:00 midnight, New York City time, on Tuesday, January 6, 2009.
The depositary for the tender offer has advised GSK that shareholders of Genelabs have tendered and not withdrawn a total of approximately 39,250,243 shares of Genelabs common stock. These shares, together with the shares beneficially owned by GSK and its wholly-owned subsidiaries, represent approximately 88.55% of the outstanding shares of Genelabs on a fully diluted basis. Gemstone has accepted for payment all Genelabs shares tendered in the offer.
GlaxoSmithKline plc (GSK) is a global healthcare group engaged in the creation, discovery, development, manufacture and marketing of pharmaceutical and consumer health-related products.[SM]
Related Categories
Mergers and AcquisitionsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
